EFTA Document EFTA01482241
Due Diligence Report Jeffrey Epstein JP Morgan Chase EFTA01482241 Executive Summary On 12/02/2008, GS&I was requested by Mary C Casey to conduct a background investigation. Media research was conducted on Financial Trust Company. Throughout this search, the following records were researched: CSSS/FPS internal database search (JPMorgan Chase Fraud Prevention List Review), publications, regulatory sanctions and OFAC (Office of Foreign Asset Control). Please Note: All research is subjec
Summary
Due Diligence Report Jeffrey Epstein JP Morgan Chase EFTA01482241 Executive Summary On 12/02/2008, GS&I was requested by Mary C Casey to conduct a background investigation. Media research was conducted on Financial Trust Company. Throughout this search, the following records were researched: CSSS/FPS internal database search (JPMorgan Chase Fraud Prevention List Review), publications, regulatory sanctions and OFAC (Office of Foreign Asset Control). Please Note: All research is subjec
Ask AI About This Document
Extracted Text (OCR)
Technical Artifacts (4)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
i-correct.com164988742496207ReferenceLink to Specific Page
Share a direct link to a specific page in this document:
https://epsteinexposed.com/documents/sd-10-EFTA01482241?page=[page_number]Related Documents (6)
EFTA01682184
EFTA01370863
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
EFTA00014087
EFTA02367961
EFTA01977826
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.